Repurposing Disulfiram as a Chemo-Therapeutic Sensitizer: Molecular Targets and Mechanisms

Anticancer Agents Med Chem. 2022;22(17):2920-2926. doi: 10.2174/1871520621666220415102553.

Abstract

Currently, chemotherapy is still the main strategy for cancer treatment. However, chemotherapy resistance remains a challenge. Disulfiram (DSF) is an FDA-approved medicine for the treatment of alcoholism; however, it was later revealed to have anticancer properties. Importantly, numerous studies have shown that DSF can be employed as a chemotherapeutic sensitizer to enhance the anticancer efficacy of chemo-drugs in a variety of cancers. Furthermore, the combinations of DSF and chemo-drugs have been tested in clinical trials. In the review, we summarized the possible molecular targets and mechanisms of DSF to reverse chemo-resistance. We also further discussed the opportunities and challenges of DSF as a chemo-therapeutic sensitizer. In conclusion, DSF could be a potentially repurposed drug that sensitizes cancer cells to chemotherapy in the clinic.

Keywords: Disulfiram; anticancer mechanisms; chemo-therapy; chemo-therapy sensitizer; drug resistance; molecular targets.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Cell Line, Tumor
  • Copper
  • Disulfiram / pharmacology
  • Drug Repositioning
  • Humans
  • Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents
  • Copper
  • Disulfiram